NEW YORK (GenomeWeb News) – Complete Genomics has again rejected Illumina's approach to acquire the firm.

Illumina aims to consummate a deal with Complete Genomics and scupper an agreement Complete Genomics already has signed to be acquired by BGI-Shenzhen for $3.15 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.